Biofrontera Inc. to Present at the 34th Annual Roth Conference

WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the 34^th Annual Roth Conference being held March 13-15 in Laguna Niguel, California.

The conference will consist of 1-on-1 / small-group meetings, analyst-selected fireside chats, thematic industry panels and on-demand presentations by executive management from approximately 400 private and public companies in a variety of growth sectors including: Blockchain/Cryptocurrency, Business Services, Consumer / Health & Wellness, Healthcare, Resources: Oil & Gas / Meals & Mining, Technology & Media and Sustainability/ESG.

To learn more and submit a registration request, visit https://ibn.fm/ROTH2022Registration. A live audio webcast and replay of Biofrontera’s presentation will be available in the investor relations section of the Company’s website at https://investors.biofrontera-us.com.

About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Contacts

Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
[email protected]

LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
[email protected]

# # #

Disclaimer: This content is distributed by The GlobeNewswire